Kodiak Sciences Inc. (KOD) Stock Price & Analysis

Kodiak Sciences Inc. (KOD) rose 0.00% to USD 41.41 as of July 25, 2026 at 02:23 UTC, according to Nexqual real-time market data.

KOD last closed at USD 41.41; the session ranged USD 41.12–42.9 on volume of 498,814 shares. Market capitalization is —, with a 52-week range of USD 6.21–47.84 (NGM). Source: Nexqual, July 25, 2026 at 02:23 UTC.

Key Statistics (as of July 25, 2026 at 02:23 UTC)

Technical Analysis (KOD)

Nexqual's technical model rates KOD "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 02:23 UTC.

From Kodiak Sciences Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• We are advancing our platform technology to embed small molecules and other active pharmaceutical ingredients ("API") into our proprietary biopolymer backbone to enable high drug-antibody-ratio ("DAR") medicines.
• Beyond its clinical pipeline, Kodiak is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients ("API"), into Kodiak's proprietary biopolymer backbone to enable high drug-antibody ratio ("DAR") medicines.
• Vabysmo demonstrated non-inferior visual acuity outcomes versus Eylea in Phase 3 trials across wet AMD, DME and RVO, with extended dosing intervals of up to every 16 weeks in a meaningful proportion of patients. 6   Regeneron's Eylea HD is a major competitive product, with FDA approvals across wet AMD, DME, DR and RVO.
• Drug Development In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations, and biologics under the FDCA, the Public Health Service Act, or PHSA, and their implementing regulations.

Partnerships

• In addition to advancing our pipeline, we have made progress in process development and commercial scale manufacturing, including the commissioning and regulatory approval of Ursus, our dedicated commercial-scale drug substance manufacturing facility that was custom-designed and built in collaboration with Lonza, a leading drug contract manufacturing firm.
• Antibody Biopolymer Conjugate Drug Substance Manufacturing In August 2020, we entered into a manufacturing agreement with Lonza for the clinical and commercial supply of the Company's antibody biopolymer conjugate drug substance which included a custom-built manufacturing facility.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:23 UTC. This page is informational and not investment advice.